title: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
authors.forename: Glenn N
authors.initials: GN
authors.lastname: Levine
authors.forename: Anthony V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: Peter
authors.initials: P
authors.lastname: Berger
authors.forename: Peter E
authors.initials: PE
authors.lastname: Clark
authors.forename: Robert H
authors.initials: RH
authors.lastname: Eckel
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Keating
authors.forename: Richard V
authors.initials: RV
authors.lastname: Milani
authors.forename: Arthur I
authors.initials: AI
authors.lastname: Sagalowsky
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
authors.forename: Neil
authors.initials: N
authors.lastname: Zakai
mesh_terms: D026683:Advisory Committees; D000570:American Cancer Society; D000572:American Heart Association; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D012955:Societies, Medical; D014481:United States
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone